AL-ADTRAN
13.3.2023 14:01:39 CET | Business Wire | Press release
Adtran®, Inc., (NASDAQ:ADTN), the leading provider of next-generation open and disaggregated networking solutions, and Satelles, Inc., the leading supplier of secure time and location technology using low-earth orbit (LEO) satellites, today announced a strategic partnership. The collaboration will enable operators of critical infrastructure to safeguard their timing networks with Satellite Time and Location (STL) technology. By integrating Satelles’ STL into its Oscilloquartz network synchronization products, Adtran will provide an alternative to GNSS systems or a way to augment them with enhanced reliability and security. With the ability to deliver highly precise PNT service, even in GNSS-denied applications, STL offers a vital resource for mobile operators, power utility companies, government, scientific research and more.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230313005475/en/
Adtran’s partnership with Satelles will further strengthen its aPNT+™ solution. (Photo: Business Wire)
“We’re pleased to be working with Adtran’s Oscilloquartz division to integrate STL into its portfolio of PTP network timing devices. Together, we’re enabling even more customers to benefit from their game-changing aPNT+™ technology,” said Christina Riley, VP and GM of commercial enterprise solutions at Satelles. “Leveraging LEO signals that are 1,000 times stronger than GNSS, our STL solution is transforming the PNT industry. It’s ideal for providing accurate, reliable timing where GNSS can’t reach, such as indoor locations. And in settings where it is possible to receive GNSS signals, STL complements it with additional PNT services to improve resiliency. Easy and affordable to install, STL also offers new levels of security for synchronization network infrastructure.“
STL provides augmented and secure backup for GPS or other GNSS by harnessing encrypted signals transmitted via LEO satellites. It ensures timing and location information that is highly precise, robustly secure, and accessible worldwide. STL is effectively impervious to cyberattacks and is far less susceptible to GNSS vulnerabilities such as signal disruption and manipulation. And because STL signals are up to 1,000 times stronger than GNSS, they can easily reach into buildings and other hard-to-reach locations. Through its partnership with Satelles, Adtran’s Oscilloquartz division will incorporate these benefits into its end-to-end timing toolkit. What’s more, as well as integrating STL into its grandmaster clocks, it will develop miniature M.2 form factor STL receiver modules for third-party product integration.
“We’re excited to offer Satelles’ innovative STL technology as the perfect addition to our portfolio. Reliable, precise and secure, STL is an excellent source of alternative PNT services that’s ideal for use in situations where distributed PTP is unavailable. It also creates new market opportunities for indoor 5G and data center use cases. By incorporating it into our solutions, we’ll empower operators of mission-critical networks to bring robust timing to the most challenging environments and remove the expense of installing outdoor antennas and coring through concrete,” commented Gil Biran, GM of Oscilloquartz, Adtran. “This partnership reinforces our commitment to providing the most advanced and reliable network timing solutions available, and we look forward to bringing the advantages of STL to customers around the world.”
About Adtran
Adtran, Inc. is a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. Adtran, Inc. is a wholly-owned subsidiary of ADTRAN Holdings, Inc. (NASDAQ:ADTN and FSE: QH9). Find more at Adtran, LinkedIn and Twitter.
About Satelles
Satelles protects critical infrastructure by providing STL as an alternative positioning, navigation, and timing (PNT) technology that delivers stability, reliability, and trust required by commercial enterprises and government entities. STL’s secure signal from low Earth orbit (LEO) is resilient to regional outages of GPS and other GNSS. Customers turn to Satelles for a primary source of PNT, and STL also safeguards against devastating attacks to GPS/GNSS capable of disrupting or disabling electrical grids, wireless communications networks, financial systems, and other private and public infrastructure. Built on a foundation of expertise in the public sector, Satelles delivers first-to-market proven technology that is sold commercially throughout the world today. Learn more at www.satelles.com.
Published by
Adtran, Inc.
www.adtran.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230313005475/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
